GSK Files Blockbuster Hopeful Shingrix With FDA

The shingles vaccine is considered one of the products with the biggest commercial potential for GSK in the near-term.

GlaxoSmithKline PLC has filed the shingles vaccine Shingrix with FDA, positioning the company for a late 2017 launch of what is expected to be a significant revenue generator. The company announced the BLA filing for Shingrix for the prevention of herpes zoster (shingles) in people age 50 and older on Oct. 24 and said it is on track to file the vaccine in Canada and Europe also in 2016.

The regulatory filing is an important milestone for GSK because Shingrix is considered one of the products in GSK’s pipeline...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip